close

Trubion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of protein therapeutic product candidates for the treatment of autoimmune and inflammatory diseases and cancer. The company, in a collaboration with Wyeth, is conducting a phase IIb clinical trial for its lead product candidate, TRU-015, for the treatment of rheumatoid arthritis. The company also offers TRU-016, a phase II/II clinical evaluation product and a novel CD37-targeted therapy for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia and certain autoimmune and inflammatory disease indications. It also has collaboration agreement with Wyeth for the development and commercialization of SBI-087 for the treatment of rheumatoid arthritis and SBI-087 for the treatment of systemic lupus erythematosus, as well as other therapeutics directed to CD20, an antigen that is a validated clinical target present on B cells. The company was founded in 1999 and is headquartered in Seattle, Washington.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	4.60
Volume	11725
Volume Avg	98652
52 Week High	4.95
52 Week Low	2.29
PE	N/A
PE (group average)	N/A
EPS Year	-1.16
EPS change Q/Q	-3.45%
EPS change Q/Q Yr ago	-50.82%
EPS change Q/Q next Q est	-23.08%
EPS change Y/Y	-32.56%
REV change Q/Q	5.77%
REV change Q/Q Yr ago	30.95%
EPS next Q est	-0.39
EPS next Y est	-1.33
Divident Annual	0.00
Dividend Yield	0%